{"id":"https://openalex.org/W2069376128","doi":"https://doi.org/10.1097/00004714-199606002-00005","title":"Dose-Response Relationship With Venlafaxine","display_name":"Dose-Response Relationship With Venlafaxine","alternate_titles":[],"publication_year":1996,"publication_date":"1996-06-01","ids":{"openalex":"https://openalex.org/W2069376128","doi":"https://doi.org/10.1097/00004714-199606002-00005","mag":"2069376128","pmid":"https://pubmed.ncbi.nlm.nih.gov/8784645"},"language":"en","primary_location":{"id":"doi:10.1097/00004714-199606002-00005","doi":"https://doi.org/10.1097/00004714-199606002-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004714-199606002-00005","pdf_url":null,"source":{"id":"https://openalex.org/S76849566","display_name":"Journal of Clinical Psychopharmacology","issn_l":"0271-0749","issn":["0271-0749","1533-712X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Psychopharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2069376128"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108631433","display_name":"Jeffrey E. Kelsey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282516798","display_name":"Atrium Health Wake Forest Baptist","ror":"https://ror.org/04v8djg66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282516798","https://openalex.org/I47251452"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"JEFFREY E. KELSEY","raw_affiliation_strings":["Department of Psychiatry and Behavioral Medicine, Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry and Behavioral Medicine, Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA","institution_ids":["https://openalex.org/I1282516798"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5108631433"],"corresponding_institution_ids":["https://openalex.org/I1282516798"],"apc_list":null,"apc_paid":null,"fwci":1.2826,"has_fulltext":false,"cited_by_count":53,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.79172932,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"16","issue":"SUPPLEMENT 2","first_page":"21S","last_page":"26S"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13118","display_name":"Psychological Treatments and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venlafaxine","display_name":"venlafaxine","score":1.0},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.9909999966621399},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.7919999957084656},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.8080000281333923},{"id":"https://openalex.org/keywords/serotonin-norepinephrine-reuptake-inhibitors","display_name":"serotonin-norepinephrine reuptake inhibitors","score":0.8740000128746033},{"id":"https://openalex.org/keywords/dosing-frequency","display_name":"dosing frequency","score":0.5789999961853027},{"id":"https://openalex.org/keywords/outpatients","display_name":"outpatients","score":0.5619999766349792},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.6819999814033508}],"concepts":[{"id":"https://openalex.org/C2776466888","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine","level":4,"score":0.9294464588165283},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7973700761795044},{"id":"https://openalex.org/C83849319","wikidata":"https://www.wikidata.org/wiki/Q7295720","display_name":"Rating scale","level":2,"score":0.6762214303016663},{"id":"https://openalex.org/C2909532165","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine Hydrochloride","level":5,"score":0.6700928211212158},{"id":"https://openalex.org/C162156334","wikidata":"https://www.wikidata.org/wiki/Q473420","display_name":"Dose","level":2,"score":0.6124794483184814},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6045901775360107},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.5486404299736023},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4891095757484436},{"id":"https://openalex.org/C2776466505","wikidata":"https://www.wikidata.org/wiki/Q385555","display_name":"Hamilton Rating Scale for Depression","level":4,"score":0.48503559827804565},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.4754730761051178},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.39250099658966064},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3713439106941223},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.35839781165122986},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.35746875405311584},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3094113767147064},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.24338579177856445},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.09367749094963074},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.08859798312187195},{"id":"https://openalex.org/C138496976","wikidata":"https://www.wikidata.org/wiki/Q175002","display_name":"Developmental psychology","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069470","descriptor_name":"Venlafaxine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000553","descriptor_name":"Ambulatory Care","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009638","descriptor_name":"Norepinephrine","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D010555","descriptor_name":"Personality Inventory","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012701","descriptor_name":"Serotonin","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00004714-199606002-00005","doi":"https://doi.org/10.1097/00004714-199606002-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004714-199606002-00005","pdf_url":null,"source":{"id":"https://openalex.org/S76849566","display_name":"Journal of Clinical Psychopharmacology","issn_l":"0271-0749","issn":["0271-0749","1533-712X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:8784645","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8784645","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical psychopharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W4096420","https://openalex.org/W50948397","https://openalex.org/W141935268","https://openalex.org/W168281387","https://openalex.org/W188287245","https://openalex.org/W1796828557","https://openalex.org/W1811060604","https://openalex.org/W1930767620","https://openalex.org/W1966841478","https://openalex.org/W1981042739","https://openalex.org/W2037465712","https://openalex.org/W2050241533","https://openalex.org/W2050896313","https://openalex.org/W2061378977","https://openalex.org/W2071765053","https://openalex.org/W2121086028","https://openalex.org/W2131823335","https://openalex.org/W2404234735","https://openalex.org/W2409011936"],"related_works":["https://openalex.org/W1989995824","https://openalex.org/W2037465712","https://openalex.org/W1966078468","https://openalex.org/W2061439361","https://openalex.org/W2017130239","https://openalex.org/W2005693447","https://openalex.org/W2164706851","https://openalex.org/W2041966651","https://openalex.org/W2319612864","https://openalex.org/W192041726"],"abstract_inverted_index":{"Considerations":[0],"when":[1,76],"selecting":[2],"a":[3,29,97],"first-line":[4],"antidepressant":[5],"agent":[6],"include":[7],"the":[8,52,58,64,85],"potential":[9],"for":[10,56],"achieving":[11],"greater":[12,19],"response":[13],"with":[14],"increasing":[15],"dosages,":[16],"thereby":[17],"allowing":[18],"flexibility":[20],"in":[21,38,84,102],"dosing.":[22],"The":[23],"efficacy":[24],"and":[25,32,63,74],"dose-response":[26,98],"of":[27,87,96],"venlafaxine,":[28],"novel":[30],"serotonin":[31],"norepinephrine":[33],"reuptake":[34],"inhibitor,":[35],"was":[36,47,100],"evaluated":[37],"two":[39],"placebo-controlled":[40],"studies.":[41,104],"Both":[42],"studies":[43],"demonstrated":[44],"that":[45],"venlafaxine":[46],"efficacious":[48],"(as":[49],"determined":[50],"by":[51],"Hamilton":[53],"Rating":[54,61],"Scale":[55],"Depression,":[57],"Montgomery-Asberg":[59],"Depression":[60],"Scale,":[62],"Clinical":[65],"Global":[66],"Impressions":[67],"scale":[68],"scores),":[69],"as":[70,72],"well":[71],"safe":[73],"tolerable":[75],"administered":[77],"either":[78],"twice":[79],"or":[80],"three":[81],"times":[82],"daily":[83],"treatment":[86],"outpatients":[88],"who":[89],"had":[90],"major":[91],"depression.":[92],"In":[93],"addition,":[94],"evidence":[95],"relationship":[99],"shown":[101],"both":[103]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2069376128","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
